CD274 and familial pancreatic carcinoma: In a recent study in pancreatic cancer, Del Re et al. assessed the ability of gemcitabine plus nab-paclitaxel (i.e., a nab-drug type nanoparticle) to increase the level of PD-L1 mRNA expression, suggesting its interest as an immunomodulatory regimen to increase future chances of success for immune checkpoint inhibitors [13].